Abstract Library

#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,

#4485 Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms (NEN) treated with [177Lu]Lu-DOTA-Octreotate (LuTate) therapy over a 4.5 year period at a single high volume treatment centre

Introduction: LuTate therapy is an effective treatment for patients with somatostatin receptor expressing NEN. However, patients (pts) with functional tumours may develop an acute flare of symptoms during or after PRRT.

Conference:

Presenting Author: Kong G

Authors: Neeson L, Boehm E, Chiang C, Michael M, Sachithanandan N,

Keywords: PRRT, NET, high-risk, flare, outcomes, NEN, single centre,

#4338 Spot urine 5-HIAA creatinine ratio is comparable to 24hr urine collection for diagnosis of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) constitutes up to 20% of functional neuroendocrine neoplasms and can lead to carcinoid crisis (CC), a potentially fatal complication during invasive procedures. Urine 5-hydroxyindoleacetic acid (5HIAA) is the preferred diagnostic biomarker for CS and prognostic marker for CC. 5HIAA is collected over 24-hours with strict dietary restriction for the 2 days prior as well as the day of the collection. False positive and negative results can occur due to under and over-collection. Patient inconvenience also contributes to the low request rate of this test.

Conference:

Presenting Author: Kong G

Authors: Chiang C, Gamage I, Del Olmo-Garcia M, Pasanen L, Wong H,

Keywords: carcinoid syndrome, carcinoid crisis, urine 5-HIAA, biomarker,

#4303 Carcinoid crisis: Insights from an ENETS Center of Excellence

Introduction: Neuroendocrine neoplasms (NENs) are rare tumours, with up to 30% being functional and associated with carcinoid syndrome (CS). CS commonly presents with flushing, diarrhoea, and hemodynamic instability, and can progress to carcinoid crisis (CC), a severe, potentially fatal complication during surgery or other invasive procedures. The use of prophylactic octreotide infusion peri-operatively remains controversial. The lack of a universal CC definition also poses a challenge for standardised outcome assessments.

Conference:

Presenting Author: Del Olmo-Garcia M

Authors: Del Olmo-Garcia M, Kong G, Wong H, Michael M, Ismail H,

Keywords: carcinoid syndrome, carcinoid crisis, somatostatin analogue, peri-operative management,

#4239 Implementation of a new, nurse-led clinic (NLC) for neuroendocrine tumor (NET) patients

Introduction: There is international evidence supporting nurse-led services for people with chronic diseases in reducing hospitalisations, symptom improvement and lifestyle, and patient satisfaction. Patients with NET often have high symptoms burden and psychosocial distress in the context of indolent disease. Our centre recently implemented a (NLC) to provide complex care support for patients with NET.

Conference:

Presenting Author:

Authors: Wakelin K, Michael M, Kong G, Rogers M, Natkunarajah N,

Keywords: Nurse-led care, Multidisciplinary care, Supportive care, Symptom management, Patient support,